Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

PFIZER (PFE)
Mes dernières consult.
Most popular
Report
Delayed Quote. Delayed  - 12/15 10:00:23 pm
37.2 USD   +2.03%
12/15 DOW MOVERS : Ibm, pfe
12/15 PFIZER INC. : Announces Expiration and Results of its Private Exchan..
12/15 Germany's Merck in fresh bid to enter U.S. MS pill market
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Pfizer : UK gives Pfizer world's first over-the-counter Viagra approval

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/28/2017 | 05:04pm CET
The Pfizer logo is seen at their world headquarters in Manhattan, New York, U.S.

Pfizer's big-selling erectile dysfunction drug Viagra has been given a green light for sale without a prescription in Britain, the first country to grant it over-the-counter status.

The U.S. drugmaker said on Tuesday it was working on plans to launch the non-prescription version of the medicine, known as Viagra Connect, in the United Kingdom in the spring of 2018.

The drug will only be available in pharmacies and its supply will depend on pharmacists' assessment of its suitability for each individual.

Viagra has been one of the pharmaceutical industry's most successful prescription products since its launch in 1998, following a serendipitous discovery of its effects by researchers who had been studying it as a heart medicine.

It achieved peak worldwide sales of more than $2 billion in 2012 but sales have since declined as patents have expired, prompting Pfizer to explore extending its brand value as a non-prescription drug.

Viagra is so far the only erectile dysfunction medicine to be reclassified from "prescription only medicine" to "pharmacy" status in Britain. The change follows a lengthy review by the Medicines and Healthcare products Regulatory Agency (MHRA).

Pfizer will continue to make Viagra available as a prescription drug but the option of also buying it over-the-counter is likely to reduce demand for potentially ineffective and dangerous fakes.

"It's important men feel they have fast access to quality and legitimate care, and do not feel they need to turn to counterfeit online supplies which could have potentially serious side effects," said Mick Foy, the MHRA's group manager in vigilance and risk management of medicines.

(Reporting by Ben Hirschler; Editing by Alexander Smith and Mark Potter)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER
12/16 PFIZER : US regulators approve Pfizers Remicade biosimilar
12/16 PFIZER : weighs `strategic options` for newly FDA-approved Remicade biosim, its ..
12/15 DOW MOVERS : Ibm, pfe
12/15 PFIZER INC. : Announces Expiration and Results of its Private Exchange Offer for..
12/15 PFIZER : Kirsten Lund-Jurgensen Named to Executive Committee of Manufacturers As..
12/15 PFIZER : U.S. Food And Drug Administration Extends Action Date For XELJANZ (Tofa..
12/15 Germany's Merck in fresh bid to enter U.S. MS pill market
12/15 PFIZER : `No plans to launch second approved Remicade biosimilar in US`
12/15 PFIZER : Fda approves new pfizer biosimilar
12/15 PFIZER : Preliminary Data from Servier and Pfizer's UCART19 Product Candidate Sh..
More news
News from SeekingAlpha
12/15 FDA OKs Pfizer's Xeljanz for psoriatic arthritis; shares up 1% premarket
12/15 PFIZER : Strong Cash Flow, Improving Pipeline, And A Dividend Hike Coming Up
12/14 Test Portfolio Results And Introducing A New Quality Portfolio
12/14 Pfizer launches Phase 3 program for JAK1 inhibitor PF-04965842 in atopic derm..
12/14 More Positives For Roche, The Core Biotech For The Long Run
Financials ($)
Sales 2017 52 550 M
EBIT 2017 19 881 M
Net income 2017 10 958 M
Debt 2017 23 944 M
Yield 2017 3,43%
P/E ratio 2017 19,95
P/E ratio 2018 17,20
EV / Sales 2017 4,68x
EV / Sales 2018 4,54x
Capitalization 222 B
Chart PFIZER
Duration : Period :
Pfizer Technical Analysis Chart | PFE | US7170811035 | 4-Traders
Technical analysis trends PFIZER
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 38,2 $
Spread / Average Target 2,8%
EPS Revisions
Managers
NameTitle
Ian C. Read Chairman & Chief Executive Officer
Albert Bourla Chief Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
Mikael Dolsten President-Worldwide Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER12.25%221 738
JOHNSON & JOHNSON22.95%382 722
NOVARTIS13.09%221 731
ROCHE HOLDING LTD.3.91%212 270
MERCK AND COMPANY-4.86%153 386
AMGEN21.32%128 515